IN THE SPOTLIGHT

Commentary on early survival gains from adding radiotherapy to ımmunotherapy in bone-metastatic NSCLC

Commentary on early survival gains from adding radiotherapy to ımmunotherapy in bone-metastatic NSCLC

NICE Endorses Chemo-Free First-Line Option for EGFR NSCLC

NICE Endorses Chemo-Free First-Line Option for EGFR NSCLC

Survival patterns and mutation profiles in never- and light-smokers with stage IV NSCLC

Survival patterns and mutation profiles in never- and light-smokers with stage IV NSCLC

Clinical characteristics and treatment of EGFR exon 19 L747 mutation in advanced NSCLC: a retrospective study

Clinical characteristics and treatment of EGFR exon 19 L747 mutation in advanced NSCLC: a retrospective study

Third‐Generation EGFR‐TKIs in T790M‐Negative NSCLC After First/Second‐Generation EGFR‐TKI Failure: A Retrospective Study

Third‐Generation EGFR‐TKIs in T790M‐Negative NSCLC After First/Second‐Generation EGFR‐TKI Failure: A Retrospective Study

Zidesamtinib Provides Hope as New Option for ROS1+ NSCLC

Zidesamtinib Provides Hope as New Option for ROS1+ NSCLC

Emerging Targets in NSCLC beyond EGFR, ALK & ROS .pptx

Emerging Targets in NSCLC beyond EGFR, ALK & ROS .pptx

Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial

Efficacy and Safety of Atezolizumab Plus Bevacizumab in Patients With Advanced NSCLC Who Received Pretreatment With EGFR-TKIs (ML41256): A Multicenter, Prospective, Single-Arm, Phase 2 Trial